Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 5 30 versus AUROVELA 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 5 30 versus AUROVELA 1 20.
AUROVELA 1.5/30 vs AUROVELA 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combined estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin (FSH, LH) release via negative feedback on pituitary; norethindrone acetate inhibits ovulation by suppressing LH surge, altering cervical mucus and endometrial lining.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Prevention of pregnancyTreatment of moderate acne vulgaris in females at least 15 years old who have achieved menarche and desire contraceptionOff-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
Prevention of pregnancyOral contraception
One tablet (1.5 mg norethindrone acetate, 30 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
None Documented
None Documented
Norethindrone: 8-10 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved within 5-7 days.
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
Ethinyl estradiol undergoes hepatic CYP3A4 metabolism. Norethindrone acetate is deacetylated to norethindrone, which is metabolized primarily via reduction and conjugation (CYP3A4 minor role).
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes first-pass metabolism. Norethindrone: primarily metabolized by CYP3A4, also undergoes first-pass metabolism.
Renal (25% norethindrone metabolites, 5% ethinyl estradiol metabolites) and fecal (60% norethindrone, 30% ethinyl estradiol); <1% unchanged drug in urine.
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Norethindrone: 75% bound to albumin and SHBG; Ethinyl estradiol: 95-98% bound to albumin.
Norethindrone: ~61% bound to albumin, 36% to SHBG; ethinyl estradiol: ~98% bound to albumin.
Norethindrone: 3.5-4.5 L/kg; Ethinyl estradiol: 3-5 L/kg; reflects extensive tissue distribution.
Norethindrone: ~2.5–4 L/kg; ethinyl estradiol: ~2.5–4 L/kg. Distribution into breast milk and body tissues.
Norethindrone: 65% (first-pass effect); Ethinyl estradiol: 40-50% (first-pass effect).
Oral: norethindrone ~64%, ethinyl estradiol ~45–55% due to first-pass metabolism.
No specific dose adjustment recommended. Use with caution in severe renal impairment (GFR < 30 mL/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to potential fluid retention and hypertension.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution, monitor liver function.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh A or B; monitor liver function and consider alternative contraception if liver disease is active.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily).
Not indicated for use before menarche. For post-menarcheal adolescents, same dose as adults: one tablet orally once daily.
Not indicated for use in postmenopausal women.
Not indicated for use after menopause. For perimenopausal women, same dose as adults until menopause; monitor for thromboembolic risk due to age and comorbidities.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptives (CHCs). Risk increases with age and number of cigarettes smoked. Women over 35 who smoke should not use CHCs.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age and amount smoked, especially in women over 35.
Increased risk of thromboembolic events, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease, hypertension. Should be discontinued if jaundice, visual disturbances, or migraine develops. Monitor blood pressure, glucose, and lipids in at-risk patients.
["Increased risk of thromboembolic events, especially in smokers over 35","Hepatic neoplasia risk","Gallbladder disease","Carbohydrate and lipid metabolism effects","Elevated blood pressure","Ocular lesions (e.g., retinal thrombosis)","Headache/migraine exacerbation","Unscheduled bleeding/spotting"]
Thrombophlebitis or thromboembolic disorders, history of deep vein thrombosis or pulmonary embolism, cerebrovascular or coronary artery disease, known or suspected breast cancer, endometrial cancer or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenomas or carcinomas, known or suspected pregnancy, hypersensitivity to any component, and women over 35 who smoke.
["Thrombophlebitis or thromboembolic disorders","History of deep vein thrombosis or pulmonary embolism","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Pregnancy","Active liver disease or benign/malignant liver tumors","Smoking and age >35, especially heavy smoking","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions. Take with food if nausea occurs.
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. High-fat meals can increase drug absorption but not clinically relevant. Alcohol does not interact directly but may impair adherence.
AUROVELA 1.5/30 (ethinyl estradiol 30 mcg, levonorgestrel 1.5 mg) is contraindicated in pregnancy. First trimester exposure is not associated with a significant increase in major malformations; however, hormonal contraceptives should be discontinued if pregnancy is suspected. Second and third trimester exposure may increase risks of fetal genital tract abnormalities (e.g., hypospadias with progestins) and potential long-term effects, though data are limited due to contraindication.
First trimester: No increased risk of major birth defects based on large epidemiological studies. Second and third trimesters: Associated with increased risk of intrauterine growth restriction (IUGR), preterm birth, and gestational hypertension if hormonal exposure continues. Close fetal monitoring recommended.
AUROVELA 1.5/30 is excreted in breast milk in small amounts. Ethinyl estradiol M/P ratio approximately 0.4; levonorgestrel M/P ratio approximately 0.6. The combination may reduce milk production and composition, especially in early postpartum. Use is not recommended during breastfeeding unless no alternative; if used, monitor infant for jaundice and weight gain.
Excreted in breast milk in small amounts (M/P ratio ~0.3). Not known to cause adverse effects in nursing infants at typical doses. Use with caution; may reduce milk production.
AUROVELA 1.5/30 is contraindicated in pregnancy; no dose adjustments apply. Pharmacokinetic changes in pregnancy (e.g., increased hepatic metabolism, increased plasma volume) are not relevant as use is contraindicated. Discontinue immediately if pregnancy occurs.
No dose adjustment required for Auvela 1/20; however, current guidelines recommend discontinuing combination hormonal contraceptives as soon as pregnancy is confirmed due to theoretical risks. Progestin-only or non-hormonal methods are preferred during pregnancy.
Category C
Category C
AUROVELA 1.5/30 is a monophasic oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg. It is indicated for contraception and management of menstrual disorders. Note increased thrombotic risk in smokers over 35. Adjust dosing if patient is on enzyme-inducing antiepileptics or rifampin. Breakthrough bleeding common in first 3 cycles.
AUROVELA 1/20 (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) is a monophasic oral contraceptive. Advise patients to take at the same time daily to maintain consistent hormone levels. Missed pill protocol: if one pill is missed, take it as soon as remembered; if two or more are missed, use backup contraception for 7 days. Monitor for breakthrough bleeding, especially in the first 3 cycles. Contraindicated in smokers over 35, hypertension, history of thromboembolism, migraine with aura, or liver disease.
Take one tablet daily at same time, with or without food.If missed pill, follow package instructions; use backup contraception if needed.Common side effects: nausea, breast tenderness, breakthrough bleeding; usually subside.Monitor for symptoms of thrombosis: leg pain, swelling, chest pain, shortness of breath.No protection against STIs; use condoms for prevention.Inform your doctor if you smoke, have migraines with aura, or history of blood clots.
Take one tablet daily at the same time, preferably with food to reduce nausea.If you miss a pill, refer to the package insert for specific instructions; use backup contraception if needed.Common side effects include nausea, breast tenderness, and breakthrough bleeding; these usually improve after 2-3 cycles.Do not smoke while taking this medication due to increased risk of blood clots.This medication does not protect against sexually transmitted infections (STIs).Contact your healthcare provider if you experience severe headache, chest pain, leg pain/swelling, or vision changes.